Exploiting potential molecular compounds for treating testicular seminoma by targeting immune related genes.

ABSTRACT:

Background

In cases of advanced seminoma, up to 30% of patients may manifest cisplatin resistance, necessitating aggressive salvage therapy, with a consequent 50% risk of mortality attributable to cancer. Nevertheless, beyond chemotherapy and radiotherapy, no further therapeutic modalities have been implemented for these patients.

Methods

The study commenced with the identification of differentially expressed immune-related genes, which were subsequently subjected to clustering using WGCNA. Prognostic signature construction ensued through the execution of univariable Cox regression, lasso regression, and multivariable Cox regression analyses. To validate the prognostic signature, the TCGA-TGCT and GSE99420 cohorts were employed, with assessments conducted via PFS, C-index, D

SUBMITTER: Cui Y 

PROVIDER: S-EPMC11580341 | biostudies-literature | 2024 Nov

REPOSITORIES: biostudies-literature